Asset
IOV-2001
Iovance Biotherapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04155710 | phase1 | completed | 2020-02-19 | 2024-11-11 | Iovance Biotherapeutics, Inc. | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL |
FDA applications (0)
This company has no applications containing this asset.